> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# HighField’s TLL-018 tops tofacitinib on ACR50 in Phase 3 RA
- URL: https://chinapharmadesk.com/highfield-tll-018-acr50-phase3-brief-2026-11-12/
- Published: 2026-11-12T04:46:44.000Z
- Updated: 2026-11-12T08:41:27.000Z
- Description: Late-breaking ACR data: JAK1/TYK2 inhibitor ginoxitinib posted a 73% ACR50 rate at week 24 versus 49.5% for tofacitinib.
- Author: LinYi
- Tags: Desk brief, Pipeline

**What moved.** HighField Biopharmaceuticals reported Phase 3 TARA results for ginoxitinib (TLL-018), a selective JAK1/TYK2 inhibitor, as a late-breaking oral at ACR Convergence 2026 in active rheumatoid arthritis after inadequate response or intolerance to at least one bDMARD, according to company materials released around the meeting.

**The number.** At week 24, ACR50 was **73.0%** on ginoxitinib versus **49.5%** on tofacitinib 5 mg BID (difference 23.5 percentage points; p<0.0001). The company says China Phase 3 RA topline was positive in April 2026, with CDE breakthrough therapy designation in July 2026; a CSU Phase 3 also read out positive in January 2026.

**Why it matters.** Head-to-head superiority language against a marketed JAK is rare and commercially loud. For industry readers, watch how safety (infections, herpes zoster, VTE) and prior JAK exposure (38.9% in this trial) are framed in filings—and whether overseas rights become a live BD conversation.

*Industry information only—not medical or investment advice.*